Like APLP2, the APP protein expression levels are congruent with those previously reported [26, 27] showing a 2.3-fold higher protein expression of APP in the MND-affected spinal cord samples and significantly different to the control group (Fig. 1D, E). This evidence concerns the gene APP and mild neurocognitive disorder.